董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Philippe Deschamps | 男 | Independent Director | 63 | 未披露 | 0.90 | 2026-03-19 |
| Christopher Calise | 男 | Director | 52 | 未披露 | 36.87 | 2026-03-19 |
| David Mehalick | 男 | Chairman and Chief Executive Officer and President | 57 | 59.70万美元 | 33.02 | 2026-03-19 |
| Daniel Yerace | 男 | Director and Vice President of Operations | 43 | 45.20万美元 | 7.05 | 2026-03-19 |
| Tara Maria DeSilva | 女 | Independent Director | 57 | 未披露 | 0.90 | 2026-03-19 |
| Christopher Cochran | 男 | Independent Director | 56 | 未披露 | 0.90 | 2026-03-19 |
| Brian Cogley | 男 | Chief Financial Officer and Director | 39 | 31.04万美元 | 2.25 | 2026-03-19 |
| Gene Salkind | 男 | Independent Director | 72 | 未披露 | 1.32 | 2026-03-19 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David Mehalick | 男 | Chairman and Chief Executive Officer and President | 57 | 59.70万美元 | 33.02 | 2026-03-19 |
| Daniel Yerace | 男 | Director and Vice President of Operations | 43 | 45.20万美元 | 7.05 | 2026-03-19 |
| Brian Cogley | 男 | Chief Financial Officer and Director | 39 | 31.04万美元 | 2.25 | 2026-03-19 |
| Christine Sheehy | 女 | Secretary and Vice President of Compliance | 58 | 7.50万美元 | 6.40 | 2026-03-19 |
董事简历
中英对照 | 中文 | 英文- Philippe Deschamps
-
Philippe Deschamps，Deschamps先生自2014年6月起担任我们的首席执行官，总裁兼董事。此前，Deschamps从2013年10月到2014年6月担任Neurohabilitation Corporation（我们的全资子公司）总裁。从2012年2月到2013年10月，他曾担任MediaMedia Health公司（营销服务公司）的首席执行官，在那里他曾开发建议将MediaMedia Health公司出售给其私人股本赞助商。在此之前，Deschamps先生曾在GSW Worldwide（最近担任总裁兼首席执行官）和百时美施贵宝（Bristol Myers Squibb）担任各种职务，包括神经科学营销总监。Deschamps先生获得了理学学士学位。1985年获加拿大渥太华大学化学学士学位。
Philippe Deschamps has served as the President and CEO of ChitogenX Inc. (formerly Ortho Regenerative Technologies), where he is focused primarily on expansion of commercial es for the company's proprietary bio polymer drug combination products. From 2012 to 2020, he co founded and served as CEO of Heli Medical Technologies (Nasdaq: HSDT), a neurotech company. From 2002 to 2011, he served as President and CEO of GSW Worldwide, a leading healthcare commercialization company, and from 2011 to 2012 served as CEO of MediMedia Health, a private equity owned company. Prior to his CEO experience he spent 13 years at Bristol Myers Squibb (NYSE: BMY) from 1986 to 1998, including serving as director of neuroscience marketing from where he oversaw the company's neuroscience products including Bpar and Serzone and Stadol NS. Mr. Deschamps also holds the position as President of Deschamps Global Commercialization LLC, a healthcare commercialization consulting company he founded where he has served clients as a consultant in the pharmaceutical and medical tech indtries from 2020 to 2022. Mr. Deschamps received a BSc. from the University of Ottawa in Canada. - Philippe Deschamps，Deschamps先生自2014年6月起担任我们的首席执行官，总裁兼董事。此前，Deschamps从2013年10月到2014年6月担任Neurohabilitation Corporation（我们的全资子公司）总裁。从2012年2月到2013年10月，他曾担任MediaMedia Health公司（营销服务公司）的首席执行官，在那里他曾开发建议将MediaMedia Health公司出售给其私人股本赞助商。在此之前，Deschamps先生曾在GSW Worldwide（最近担任总裁兼首席执行官）和百时美施贵宝（Bristol Myers Squibb）担任各种职务，包括神经科学营销总监。Deschamps先生获得了理学学士学位。1985年获加拿大渥太华大学化学学士学位。
- Philippe Deschamps has served as the President and CEO of ChitogenX Inc. (formerly Ortho Regenerative Technologies), where he is focused primarily on expansion of commercial es for the company's proprietary bio polymer drug combination products. From 2012 to 2020, he co founded and served as CEO of Heli Medical Technologies (Nasdaq: HSDT), a neurotech company. From 2002 to 2011, he served as President and CEO of GSW Worldwide, a leading healthcare commercialization company, and from 2011 to 2012 served as CEO of MediMedia Health, a private equity owned company. Prior to his CEO experience he spent 13 years at Bristol Myers Squibb (NYSE: BMY) from 1986 to 1998, including serving as director of neuroscience marketing from where he oversaw the company's neuroscience products including Bpar and Serzone and Stadol NS. Mr. Deschamps also holds the position as President of Deschamps Global Commercialization LLC, a healthcare commercialization consulting company he founded where he has served clients as a consultant in the pharmaceutical and medical tech indtries from 2020 to 2022. Mr. Deschamps received a BSc. from the University of Ottawa in Canada.
- Christopher Calise
-
Christopher Calise，本公司首席财务官，自本公司成立起担任董事，在金融和保险行业拥有超过15年的经验，一直负责制定Crown Global的战略愿景，Crown Global是一家国内和国际私募保险控股公司，以及自2010年起监督其日常管理，包括财务、运营和销售。他还与内部和外部销售与市场营销密切合作，开发新的产品计划，以及评估新的市场。在加入Crown Global之前，他从2001年到2009年担任LSC Investors，LLC的负责人，在那里他为The Second City，Inc.和Narciso Rodriguez提供咨询，并重组了Phillips de Pury&Luxembourg，这是一家大型全球拍卖行。从1999年到2001年，他是Crown Capital Group，Inc.的合伙人，这是一家私人股本投资公司，专注于帮助中等市场公司建立长期价值，也是Fresh Direct，LLC的创始成员之一。1997年至1999年，Calise先生还是Pricewaterhouse芝加哥办事处工业产品集团的顾问。Calise先生是Song4Life and Student Finance League Inc.的董事会成员。Calise先生获得了芝加哥大学经济学学士学位，以及保险和金融方面的认证。
Christopher Calise has over 15 years of experience in the finance and insurance indtries and has been responsible for setting the strategic vision for Crown Global, a domestic and international private placement insurance holding company, as ll as overseeing its day to day management, including finance, operations and sales, since 2010. He also works closely with both internal and external sales and marketing in the development of new product initiatives, as ll as evaluating new markets. Prior to joining Crown Global, Mr. Calise was a principal at LSC Investors, LLC, from 2001 to 2009, where he advised The Second City, Inc. and Narciso Rodriguez and restructured Phillips de Pury & Luxembg, a large global auction hoe. From 1999 to 2001, he was an associate with Crown Capital Group, Inc., a private equity investment firm focused on assisting middle market companies build value over the long term and was one of the founding members of Fresh Direct, LLC. Mr. Calise was also a consultant with the Indtrial Products Group at PriceWaterhoe in its Chicago office, from 1997 to 1999. Mr. Calise is a member of the board of Song4Life and Student Finance League Inc. Mr. Calise received a Bachelor of Arts in Economics from the University of Chicago, as ll as certifications in insurance and finance. - Christopher Calise，本公司首席财务官，自本公司成立起担任董事，在金融和保险行业拥有超过15年的经验，一直负责制定Crown Global的战略愿景，Crown Global是一家国内和国际私募保险控股公司，以及自2010年起监督其日常管理，包括财务、运营和销售。他还与内部和外部销售与市场营销密切合作，开发新的产品计划，以及评估新的市场。在加入Crown Global之前，他从2001年到2009年担任LSC Investors，LLC的负责人，在那里他为The Second City，Inc.和Narciso Rodriguez提供咨询，并重组了Phillips de Pury&Luxembourg，这是一家大型全球拍卖行。从1999年到2001年，他是Crown Capital Group，Inc.的合伙人，这是一家私人股本投资公司，专注于帮助中等市场公司建立长期价值，也是Fresh Direct，LLC的创始成员之一。1997年至1999年，Calise先生还是Pricewaterhouse芝加哥办事处工业产品集团的顾问。Calise先生是Song4Life and Student Finance League Inc.的董事会成员。Calise先生获得了芝加哥大学经济学学士学位，以及保险和金融方面的认证。
- Christopher Calise has over 15 years of experience in the finance and insurance indtries and has been responsible for setting the strategic vision for Crown Global, a domestic and international private placement insurance holding company, as ll as overseeing its day to day management, including finance, operations and sales, since 2010. He also works closely with both internal and external sales and marketing in the development of new product initiatives, as ll as evaluating new markets. Prior to joining Crown Global, Mr. Calise was a principal at LSC Investors, LLC, from 2001 to 2009, where he advised The Second City, Inc. and Narciso Rodriguez and restructured Phillips de Pury & Luxembg, a large global auction hoe. From 1999 to 2001, he was an associate with Crown Capital Group, Inc., a private equity investment firm focused on assisting middle market companies build value over the long term and was one of the founding members of Fresh Direct, LLC. Mr. Calise was also a consultant with the Indtrial Products Group at PriceWaterhoe in its Chicago office, from 1997 to 1999. Mr. Calise is a member of the board of Song4Life and Student Finance League Inc. Mr. Calise received a Bachelor of Arts in Economics from the University of Chicago, as ll as certifications in insurance and finance.
- David Mehalick
-
David Mehalick，在生命科学、科技、金融服务、军事承包、娱乐和消费品等多个行业拥有超过30年的经验。他自2016年10月起担任Coeptis Therapeutics Holdings，Inc.首席执行官。自2004年3月以来，Mehalick先生担任Steeltown Consulting Group的董事总经理，该公司是一家商业咨询公司，通过该公司，他就业务组织和管理战略及解决方案向客户提供建议。Mehalick先生于2017年3月至2017年9月期间担任计算机硬件和软件公司Information Technology Procurement Sourcing，Inc.（“ITPS”）的首席财务官。2019年1月，ITPS根据美国《破产法》第11章提交了自愿重组申请。Mehalick先生于1992年3月至1995年4月担任Gruntal and Co.的第一副总裁，于1995年5月至1998年6月担任First Union Capital Markets的高级副总裁，并于1998年6月至2001年1月担任投资银行公司Ferris，Baker Watts，Inc.的高级副总裁。梅哈利克先生就读于匹兹堡大学。
David Mehalick has served as the Managing Director of Steeltown Consulting Group, a biness consulting company through which he advises clients on biness organizational and management strategies and solutions. Mr. Mehalick was the Chief Financial Officer of Information Technology Procurement Scing, Inc. ("ITPS"), a computer hardware and software company, from March 2017 to September 2017. In January 2019, ITPS filed a petition for voluntary reorganization under Chapter 11 of the U.S. Bankruptcy Code. Mr. Mehalick was the First Vice President at Gruntal and Co. from March 1992 to April 1995 and Senior Vice President at First Union Capital Markets from May 1995 to June 1998 and Senior Vice President at Ferris, Baker Watts, Inc., an investment banking firm from June 1998 to January 2001. Mr. Mehalick attended the University of Pittsburgh. - David Mehalick，在生命科学、科技、金融服务、军事承包、娱乐和消费品等多个行业拥有超过30年的经验。他自2016年10月起担任Coeptis Therapeutics Holdings，Inc.首席执行官。自2004年3月以来，Mehalick先生担任Steeltown Consulting Group的董事总经理，该公司是一家商业咨询公司，通过该公司，他就业务组织和管理战略及解决方案向客户提供建议。Mehalick先生于2017年3月至2017年9月期间担任计算机硬件和软件公司Information Technology Procurement Sourcing，Inc.（“ITPS”）的首席财务官。2019年1月，ITPS根据美国《破产法》第11章提交了自愿重组申请。Mehalick先生于1992年3月至1995年4月担任Gruntal and Co.的第一副总裁，于1995年5月至1998年6月担任First Union Capital Markets的高级副总裁，并于1998年6月至2001年1月担任投资银行公司Ferris，Baker Watts，Inc.的高级副总裁。梅哈利克先生就读于匹兹堡大学。
- David Mehalick has served as the Managing Director of Steeltown Consulting Group, a biness consulting company through which he advises clients on biness organizational and management strategies and solutions. Mr. Mehalick was the Chief Financial Officer of Information Technology Procurement Scing, Inc. ("ITPS"), a computer hardware and software company, from March 2017 to September 2017. In January 2019, ITPS filed a petition for voluntary reorganization under Chapter 11 of the U.S. Bankruptcy Code. Mr. Mehalick was the First Vice President at Gruntal and Co. from March 1992 to April 1995 and Senior Vice President at First Union Capital Markets from May 1995 to June 1998 and Senior Vice President at Ferris, Baker Watts, Inc., an investment banking firm from June 1998 to January 2001. Mr. Mehalick attended the University of Pittsburgh.
- Daniel Yerace
-
Daniel Yerace，是Coeptis Pharmaceuticals的联合创始人，并担任运营副总裁。Yerace先生在制药行业拥有超过十年的经验，是负责供应链管理、业务发展、投资组合管理和企业战略的关键战略家。Yerace先生拥有广泛的运营经验，曾在小型私营公司和世界500强跨国公司的采购、全球供应链管理、运营和业务发展方面担任领导职务。在加入Coeptis之前，Yerace先生曾担任Kadmon Pharmaceuticals全球供应链和商业业务发展高级总监。Yerace先生拥有经济学学士学位，韦恩斯堡大学工商管理硕士学位。
Daniel Yerace has over ten years of experience in the pharmaceutical industry and is a key strategist responsible for supply chain management, biness development, portfolio management, and corporate strategy. Mr. Yerace has broad operational experience and has held leadership positions in procurement, global supply chain management, operations, and biness development for small private firms and fortune 500 multi national corporations. Prior to joining Coeptis, Mr. Yerace served as Senior Director of Global Supply Chain and Commercial Biness Development for Kadmon Pharmaceuticals. Mr. Yerace holds a bachelor's degree in economics, and a masters of biness administration from Waynesburg University. - Daniel Yerace，是Coeptis Pharmaceuticals的联合创始人，并担任运营副总裁。Yerace先生在制药行业拥有超过十年的经验，是负责供应链管理、业务发展、投资组合管理和企业战略的关键战略家。Yerace先生拥有广泛的运营经验，曾在小型私营公司和世界500强跨国公司的采购、全球供应链管理、运营和业务发展方面担任领导职务。在加入Coeptis之前，Yerace先生曾担任Kadmon Pharmaceuticals全球供应链和商业业务发展高级总监。Yerace先生拥有经济学学士学位，韦恩斯堡大学工商管理硕士学位。
- Daniel Yerace has over ten years of experience in the pharmaceutical industry and is a key strategist responsible for supply chain management, biness development, portfolio management, and corporate strategy. Mr. Yerace has broad operational experience and has held leadership positions in procurement, global supply chain management, operations, and biness development for small private firms and fortune 500 multi national corporations. Prior to joining Coeptis, Mr. Yerace served as Senior Director of Global Supply Chain and Commercial Biness Development for Kadmon Pharmaceuticals. Mr. Yerace holds a bachelor's degree in economics, and a masters of biness administration from Waynesburg University.
- Tara Maria DeSilva
-
Tara Maria DeSilva，自2016年3月起担任克利夫兰诊所和凯斯西储大学医学院副教授。她担任克利夫兰诊所勒纳研究所神经科学系副主席。2010年1月至2016年2月，她担任阿拉巴马大学伯明翰分校助理教授。DeSilva博士获得美国国立卫生研究院、美国国家科学基金会和美国国家多发性硬化症学会的资助。她在许多政府和基金会科学资助审查小组任职，包括美国国立卫生研究院和美国国家多发性硬化症学会。DeSilva博士在奥尔布赖特学院获得生物化学学士学位，在宾夕法尼亚大学获得生物化学硕士和博士学位，并在哈佛医学院波士顿儿童医院完成博士后培训。
Tara Maria DeSilva has been an Associate Professor at the Cleveland Clinic and Case stern Reserve University School of Medicine since March 2016. She serves as Vice Chair for the Department of Neurosciences, Lerner Research Institute, Cleveland Clinic. She was an Assistant Professor at University of Alabama at Birmingham from January 2010 to February 2016. Dr. DeSilva receives funding from the National Institutes of Health, National Science Foundation, and the National Multiple Sclerosis Society. She serves on many government and foundation scientific grant review panels including the National Institutes of Health and National Multiple Sclerosis Society. Dr. DeSilva received her B.S. in Biochemistry from Albright College, her M.S. and Ph.D. in Biological Chemistry from the University of Pennsylvania and completed her postdoctoral training at Children's Hospital Boston, Harvard Medical School. - Tara Maria DeSilva，自2016年3月起担任克利夫兰诊所和凯斯西储大学医学院副教授。她担任克利夫兰诊所勒纳研究所神经科学系副主席。2010年1月至2016年2月，她担任阿拉巴马大学伯明翰分校助理教授。DeSilva博士获得美国国立卫生研究院、美国国家科学基金会和美国国家多发性硬化症学会的资助。她在许多政府和基金会科学资助审查小组任职，包括美国国立卫生研究院和美国国家多发性硬化症学会。DeSilva博士在奥尔布赖特学院获得生物化学学士学位，在宾夕法尼亚大学获得生物化学硕士和博士学位，并在哈佛医学院波士顿儿童医院完成博士后培训。
- Tara Maria DeSilva has been an Associate Professor at the Cleveland Clinic and Case stern Reserve University School of Medicine since March 2016. She serves as Vice Chair for the Department of Neurosciences, Lerner Research Institute, Cleveland Clinic. She was an Assistant Professor at University of Alabama at Birmingham from January 2010 to February 2016. Dr. DeSilva receives funding from the National Institutes of Health, National Science Foundation, and the National Multiple Sclerosis Society. She serves on many government and foundation scientific grant review panels including the National Institutes of Health and National Multiple Sclerosis Society. Dr. DeSilva received her B.S. in Biochemistry from Albright College, her M.S. and Ph.D. in Biological Chemistry from the University of Pennsylvania and completed her postdoctoral training at Children's Hospital Boston, Harvard Medical School.
- Christopher Cochran
-
Christopher Cochran，现任BluChip Solutions总裁，BluChip Solutions是一家复杂问题IT解决方案提供商，该实体由他于2008年创立。从2012年3月到2013年5月，科克伦先生在不同公司担任领导职务，包括担任私营体验式电视网络Velocity World Media的销售和营销执行副总裁。此外，从2010年3月到2012年2月，Cochran先生在惠普企业 Enterprise担任企业云销售主管。2008年4月至2010年1月，Cochran先生在ASGN Inc.（NYSE：ASGN）担任销售和运营执行董事，该公司前身为领先的IT服务提供商Apex Systems。2008年至2010年，Cochran先生曾任职于Mastech Digital（纳斯达克：MHH），这是一家上市公司，曾担任多个职务，包括2004年2月至2008年4月期间担任全球销售和运营高级副总裁，直接向首席执行官报告。2014年5月至2016年5月，Cochran先生担任Pine-Richland Opportunities Fund的董事会成员，该基金是一家提供员工助学金和学生奖学金的非营利性教育基金会，目前他通过匹兹堡基金会担任Christian Cochran Legacy Fund的董事。Cochran先生于1993年获得田纳西大学公共行政和国际法理学学士学位。
Christopher Cochran held leadership positions within different companies, including serving as the EVP of Sales & Marketing for Velocity World Media, a private experiential television network. Additionally, from March 2010 to February 2012, Mr. Cochran worked as an Enterprise Cloud Sales Executive for Hewlett Packard Enterprise. From April 2008 to January 2010, Mr. Cochran served as the Executive Director of Sales and Operations for ASGN Inc. (NYSE: ASGN), formerly Apex Systems, a leading provider of IT services. From 2008 to 2010, Mr. Cochran worked at Mastech Digital (Nasdaq: MHH), a publicly traded company, where he held vario roles, including Senior Vice President of Global Sales and Operations from February 2004 to April 2008, where he reported directly to the CEO. From May 2014 to May 2016, Mr. Cochran served on the Board of Trtees for the Pine Richland Opportunities Fund, a non profit educational foundation providing staff grants and student scholarships, and he currently serves as Director of the Christian Cochran Legacy Fund through the Pittsburgh Foundation. Mr. Cochran received his Bachelor of Science in Public Administration and International Law from the University of Tennessee in 1993. - Christopher Cochran，现任BluChip Solutions总裁，BluChip Solutions是一家复杂问题IT解决方案提供商，该实体由他于2008年创立。从2012年3月到2013年5月，科克伦先生在不同公司担任领导职务，包括担任私营体验式电视网络Velocity World Media的销售和营销执行副总裁。此外，从2010年3月到2012年2月，Cochran先生在惠普企业 Enterprise担任企业云销售主管。2008年4月至2010年1月，Cochran先生在ASGN Inc.（NYSE：ASGN）担任销售和运营执行董事，该公司前身为领先的IT服务提供商Apex Systems。2008年至2010年，Cochran先生曾任职于Mastech Digital（纳斯达克：MHH），这是一家上市公司，曾担任多个职务，包括2004年2月至2008年4月期间担任全球销售和运营高级副总裁，直接向首席执行官报告。2014年5月至2016年5月，Cochran先生担任Pine-Richland Opportunities Fund的董事会成员，该基金是一家提供员工助学金和学生奖学金的非营利性教育基金会，目前他通过匹兹堡基金会担任Christian Cochran Legacy Fund的董事。Cochran先生于1993年获得田纳西大学公共行政和国际法理学学士学位。
- Christopher Cochran held leadership positions within different companies, including serving as the EVP of Sales & Marketing for Velocity World Media, a private experiential television network. Additionally, from March 2010 to February 2012, Mr. Cochran worked as an Enterprise Cloud Sales Executive for Hewlett Packard Enterprise. From April 2008 to January 2010, Mr. Cochran served as the Executive Director of Sales and Operations for ASGN Inc. (NYSE: ASGN), formerly Apex Systems, a leading provider of IT services. From 2008 to 2010, Mr. Cochran worked at Mastech Digital (Nasdaq: MHH), a publicly traded company, where he held vario roles, including Senior Vice President of Global Sales and Operations from February 2004 to April 2008, where he reported directly to the CEO. From May 2014 to May 2016, Mr. Cochran served on the Board of Trtees for the Pine Richland Opportunities Fund, a non profit educational foundation providing staff grants and student scholarships, and he currently serves as Director of the Christian Cochran Legacy Fund through the Pittsburgh Foundation. Mr. Cochran received his Bachelor of Science in Public Administration and International Law from the University of Tennessee in 1993.
- Brian Cogley
-
Brian Cogley，2023年5月开始担任Coeptis Therapeutics Holdings，Inc. 首席财务官。他拥有超过15年的会计和财务经验，此前曾在两家“四大”会计师事务所担任越来越权威的职位，并曾在多个行业的多家公司的管理团队任职。Cogley先生是一名受过培训的会计师，他在Coeptis拥有15年的公司财务和会计职业生涯，在此期间，他为跨越多个行业的公司提供咨询和领导财务运营，包括生命科学、制药、金融服务和制造业。最近，Cogley先生担任CFGI，LLC会计咨询高级经理，在那里他为制药和金融服务客户提供技术会计实施和执行、临时财务总监角色、临时SEC报告经理角色、分部报告和剥离业务方面的服务。在加入CFGI之前，Cogley先生曾在NexTier Bank担任财务与会计副总裁一职，是该公司高级管理团队的成员，并领导该公司的会计和财务业务，包括总分类账、财务规划和分析、内部和外部财务报告以及人力资源。在加入NexTier之前，Cogley先生曾担任Calgon Carbon Corporation的全球现金经理一职，负责全球企业的所有日常现金决策。在加入卡尔冈炭素之前，Cogley先生是TriState Capital银行的金融分析师，负责构建其Sarbanes-Oxley控制环境、SEC/监管报告和新系统实施，同时还从事各种工艺改进项目。Cogley先生的职业生涯始于KPMG，LLP，为金融服务行业的各种客户提供审计和鉴证服务。科格利先生获得了杜肯大学会计学专业的学士学位和金融学专业的工商管理硕士学位。
Brian Cogley arrives at Coeptis with a career in corporate finance and accounting during which he advised and led the financial operations for companies spanning multiple indtries including life sciences, pharmaceuticals, financial services, and manufacturing. From February 2022 until joining Coeptis, Mr. Cogley was a Senior Manager, Accounting Advisory at CFGI, LLC where he served pharmaceutical and financial services clients in technical accounting implementations and execution, interim Controller roles, interim SEC Reporting Manager roles, segment reporting and carve out engagements. From 2017 2022 Mr. Cogley held the position of Vice President of Finance & Accounting at NexTier Bank where he was a member of the Company's senior management team and led its accounting and finance operations, including the general ledger, financial planning and analysis, internal and external financial reporting, and human resces. From 2015 2017 Mr. Cogley held the position of Global Cash Manager for Calgon Carbon Corporation, where he was responsible for all daily cash decisions across the global enterprise. From 2012 2015 Mr. Cogley was a Financial Analyst at TriState Capital Bank where he was responsible for building its Sarbanes Oxley control environment, SEC/regulatory reporting and new system implementation, while also working on vario process improvement projects. Mr. Cogley began his career at KPMG, LLP, providing audit and assurance services to a variety of clients in the financial services industry. Mr. Cogley earned a B.A. with a concentration in accounting and a Master of Biness Administration with a concentration in finance from Duquesne University. - Brian Cogley，2023年5月开始担任Coeptis Therapeutics Holdings，Inc. 首席财务官。他拥有超过15年的会计和财务经验，此前曾在两家“四大”会计师事务所担任越来越权威的职位，并曾在多个行业的多家公司的管理团队任职。Cogley先生是一名受过培训的会计师，他在Coeptis拥有15年的公司财务和会计职业生涯，在此期间，他为跨越多个行业的公司提供咨询和领导财务运营，包括生命科学、制药、金融服务和制造业。最近，Cogley先生担任CFGI，LLC会计咨询高级经理，在那里他为制药和金融服务客户提供技术会计实施和执行、临时财务总监角色、临时SEC报告经理角色、分部报告和剥离业务方面的服务。在加入CFGI之前，Cogley先生曾在NexTier Bank担任财务与会计副总裁一职，是该公司高级管理团队的成员，并领导该公司的会计和财务业务，包括总分类账、财务规划和分析、内部和外部财务报告以及人力资源。在加入NexTier之前，Cogley先生曾担任Calgon Carbon Corporation的全球现金经理一职，负责全球企业的所有日常现金决策。在加入卡尔冈炭素之前，Cogley先生是TriState Capital银行的金融分析师，负责构建其Sarbanes-Oxley控制环境、SEC/监管报告和新系统实施，同时还从事各种工艺改进项目。Cogley先生的职业生涯始于KPMG，LLP，为金融服务行业的各种客户提供审计和鉴证服务。科格利先生获得了杜肯大学会计学专业的学士学位和金融学专业的工商管理硕士学位。
- Brian Cogley arrives at Coeptis with a career in corporate finance and accounting during which he advised and led the financial operations for companies spanning multiple indtries including life sciences, pharmaceuticals, financial services, and manufacturing. From February 2022 until joining Coeptis, Mr. Cogley was a Senior Manager, Accounting Advisory at CFGI, LLC where he served pharmaceutical and financial services clients in technical accounting implementations and execution, interim Controller roles, interim SEC Reporting Manager roles, segment reporting and carve out engagements. From 2017 2022 Mr. Cogley held the position of Vice President of Finance & Accounting at NexTier Bank where he was a member of the Company's senior management team and led its accounting and finance operations, including the general ledger, financial planning and analysis, internal and external financial reporting, and human resces. From 2015 2017 Mr. Cogley held the position of Global Cash Manager for Calgon Carbon Corporation, where he was responsible for all daily cash decisions across the global enterprise. From 2012 2015 Mr. Cogley was a Financial Analyst at TriState Capital Bank where he was responsible for building its Sarbanes Oxley control environment, SEC/regulatory reporting and new system implementation, while also working on vario process improvement projects. Mr. Cogley began his career at KPMG, LLP, providing audit and assurance services to a variety of clients in the financial services industry. Mr. Cogley earned a B.A. with a concentration in accounting and a Master of Biness Administration with a concentration in finance from Duquesne University.
- Gene Salkind
-
Gene Salkind， 他是医学博士。自2007年以来，他一直任职公司董事会。他在一个宾夕法尼亚州私人诊所从事神经外科医生超过25年。他是Holy Redeemer Hospital 和Medical Center 的神经外科手术主席，以及Albert Einstein Medical Center的神经外科手术前主席。他一直担任宾夕法尼亚大学天普大学医学院的教授。他发表了多个以一般神经外科为话题的文件，已经被全世界的客座讲师所接受，被众多的董事会使用。他获得宾夕法尼亚大学哲学学士学位，坦普尔大学医学院的医学博士学位。他完成宾夕法尼亚大学的神经外科主任培训，并于1985年成为总住院医师。
Gene Salkind has been a practicing neurosurgeon for more than 35 years outside of Philadelphia, PA. He graduated from the University of Pennsylvania in 1974 with a B.A., Cum Laude, and received his medical degree from the Lewis Katz School of Medicine in 1979. He returned to the University of Pennsylvania for his neurosurgical residency and in 1985 was selected as the Chief Resident in Neurosurgery at the Hospital of the University of Pennsylvania. Since that time, he has been in a university affiliated practice of general neurological surgery. He has served as the Chief of Neurosurgery at Holy Redeemer Hospital, Albert Einstein Medical Center, and Jeanes Hospital in Philadelphia. He has authored numerous peer reviewed journal articles and has given lectures throughout the country on various neurosurgical topics. He has held professorships at the University of Pennsylvania, the Allegheny Health Education and Research Foundation, and currently at the Lewis Katz School of Medicine.Dr. Salkind is a prominent investor in the pharmaceutical arena. Past investments include Intuitive Surgical, Pharmacyclics, which grew from less than $1 per share to subsequently being acquired by Abbvie for $250 per share, and Centocor, one of the nation's largest biotechnology companies, which was acquired by Johnson & Johnson for $4.9 billion in stock. Dr. Salkind currently sits on the boards of Cure Pharmaceuticals, a leader in the biotechnology field, through its continual pursuit of redefining traditional drug delivery, and Mobiquity Technologies, Inc., a digital engagement provider. Mobiquity owns and operates a national location based mobile advertising network. The company's suite of technologies allows clients to execute personalized and relevant experiences, driving brand awareness and incremental revenue. He was previously a board member of Derm Tech International, a global leader in non invasive dermatological molecular diagnostics.In 2019, Dr. Salkind joined the Strategic Advisory Board of Bio Symetrics, a company that has built data services tools for automated pre processing, integrated analytics, and predictive modeling to make machine learning accessible to scientists and providers. Their technology serves health and hospital systems, biopharma, drug discovery and precision medicine. - Gene Salkind， 他是医学博士。自2007年以来，他一直任职公司董事会。他在一个宾夕法尼亚州私人诊所从事神经外科医生超过25年。他是Holy Redeemer Hospital 和Medical Center 的神经外科手术主席，以及Albert Einstein Medical Center的神经外科手术前主席。他一直担任宾夕法尼亚大学天普大学医学院的教授。他发表了多个以一般神经外科为话题的文件，已经被全世界的客座讲师所接受，被众多的董事会使用。他获得宾夕法尼亚大学哲学学士学位，坦普尔大学医学院的医学博士学位。他完成宾夕法尼亚大学的神经外科主任培训，并于1985年成为总住院医师。
- Gene Salkind has been a practicing neurosurgeon for more than 35 years outside of Philadelphia, PA. He graduated from the University of Pennsylvania in 1974 with a B.A., Cum Laude, and received his medical degree from the Lewis Katz School of Medicine in 1979. He returned to the University of Pennsylvania for his neurosurgical residency and in 1985 was selected as the Chief Resident in Neurosurgery at the Hospital of the University of Pennsylvania. Since that time, he has been in a university affiliated practice of general neurological surgery. He has served as the Chief of Neurosurgery at Holy Redeemer Hospital, Albert Einstein Medical Center, and Jeanes Hospital in Philadelphia. He has authored numerous peer reviewed journal articles and has given lectures throughout the country on various neurosurgical topics. He has held professorships at the University of Pennsylvania, the Allegheny Health Education and Research Foundation, and currently at the Lewis Katz School of Medicine.Dr. Salkind is a prominent investor in the pharmaceutical arena. Past investments include Intuitive Surgical, Pharmacyclics, which grew from less than $1 per share to subsequently being acquired by Abbvie for $250 per share, and Centocor, one of the nation's largest biotechnology companies, which was acquired by Johnson & Johnson for $4.9 billion in stock. Dr. Salkind currently sits on the boards of Cure Pharmaceuticals, a leader in the biotechnology field, through its continual pursuit of redefining traditional drug delivery, and Mobiquity Technologies, Inc., a digital engagement provider. Mobiquity owns and operates a national location based mobile advertising network. The company's suite of technologies allows clients to execute personalized and relevant experiences, driving brand awareness and incremental revenue. He was previously a board member of Derm Tech International, a global leader in non invasive dermatological molecular diagnostics.In 2019, Dr. Salkind joined the Strategic Advisory Board of Bio Symetrics, a company that has built data services tools for automated pre processing, integrated analytics, and predictive modeling to make machine learning accessible to scientists and providers. Their technology serves health and hospital systems, biopharma, drug discovery and precision medicine.
高管简历
中英对照 | 中文 | 英文- David Mehalick
David Mehalick，在生命科学、科技、金融服务、军事承包、娱乐和消费品等多个行业拥有超过30年的经验。他自2016年10月起担任Coeptis Therapeutics Holdings，Inc.首席执行官。自2004年3月以来，Mehalick先生担任Steeltown Consulting Group的董事总经理，该公司是一家商业咨询公司，通过该公司，他就业务组织和管理战略及解决方案向客户提供建议。Mehalick先生于2017年3月至2017年9月期间担任计算机硬件和软件公司Information Technology Procurement Sourcing，Inc.（“ITPS”）的首席财务官。2019年1月，ITPS根据美国《破产法》第11章提交了自愿重组申请。Mehalick先生于1992年3月至1995年4月担任Gruntal and Co.的第一副总裁，于1995年5月至1998年6月担任First Union Capital Markets的高级副总裁，并于1998年6月至2001年1月担任投资银行公司Ferris，Baker Watts，Inc.的高级副总裁。梅哈利克先生就读于匹兹堡大学。
David Mehalick has served as the Managing Director of Steeltown Consulting Group, a biness consulting company through which he advises clients on biness organizational and management strategies and solutions. Mr. Mehalick was the Chief Financial Officer of Information Technology Procurement Scing, Inc. ("ITPS"), a computer hardware and software company, from March 2017 to September 2017. In January 2019, ITPS filed a petition for voluntary reorganization under Chapter 11 of the U.S. Bankruptcy Code. Mr. Mehalick was the First Vice President at Gruntal and Co. from March 1992 to April 1995 and Senior Vice President at First Union Capital Markets from May 1995 to June 1998 and Senior Vice President at Ferris, Baker Watts, Inc., an investment banking firm from June 1998 to January 2001. Mr. Mehalick attended the University of Pittsburgh.- David Mehalick，在生命科学、科技、金融服务、军事承包、娱乐和消费品等多个行业拥有超过30年的经验。他自2016年10月起担任Coeptis Therapeutics Holdings，Inc.首席执行官。自2004年3月以来，Mehalick先生担任Steeltown Consulting Group的董事总经理，该公司是一家商业咨询公司，通过该公司，他就业务组织和管理战略及解决方案向客户提供建议。Mehalick先生于2017年3月至2017年9月期间担任计算机硬件和软件公司Information Technology Procurement Sourcing，Inc.（“ITPS”）的首席财务官。2019年1月，ITPS根据美国《破产法》第11章提交了自愿重组申请。Mehalick先生于1992年3月至1995年4月担任Gruntal and Co.的第一副总裁，于1995年5月至1998年6月担任First Union Capital Markets的高级副总裁，并于1998年6月至2001年1月担任投资银行公司Ferris，Baker Watts，Inc.的高级副总裁。梅哈利克先生就读于匹兹堡大学。
- David Mehalick has served as the Managing Director of Steeltown Consulting Group, a biness consulting company through which he advises clients on biness organizational and management strategies and solutions. Mr. Mehalick was the Chief Financial Officer of Information Technology Procurement Scing, Inc. ("ITPS"), a computer hardware and software company, from March 2017 to September 2017. In January 2019, ITPS filed a petition for voluntary reorganization under Chapter 11 of the U.S. Bankruptcy Code. Mr. Mehalick was the First Vice President at Gruntal and Co. from March 1992 to April 1995 and Senior Vice President at First Union Capital Markets from May 1995 to June 1998 and Senior Vice President at Ferris, Baker Watts, Inc., an investment banking firm from June 1998 to January 2001. Mr. Mehalick attended the University of Pittsburgh.
- Daniel Yerace
Daniel Yerace，是Coeptis Pharmaceuticals的联合创始人，并担任运营副总裁。Yerace先生在制药行业拥有超过十年的经验，是负责供应链管理、业务发展、投资组合管理和企业战略的关键战略家。Yerace先生拥有广泛的运营经验，曾在小型私营公司和世界500强跨国公司的采购、全球供应链管理、运营和业务发展方面担任领导职务。在加入Coeptis之前，Yerace先生曾担任Kadmon Pharmaceuticals全球供应链和商业业务发展高级总监。Yerace先生拥有经济学学士学位，韦恩斯堡大学工商管理硕士学位。
Daniel Yerace has over ten years of experience in the pharmaceutical industry and is a key strategist responsible for supply chain management, biness development, portfolio management, and corporate strategy. Mr. Yerace has broad operational experience and has held leadership positions in procurement, global supply chain management, operations, and biness development for small private firms and fortune 500 multi national corporations. Prior to joining Coeptis, Mr. Yerace served as Senior Director of Global Supply Chain and Commercial Biness Development for Kadmon Pharmaceuticals. Mr. Yerace holds a bachelor's degree in economics, and a masters of biness administration from Waynesburg University.- Daniel Yerace，是Coeptis Pharmaceuticals的联合创始人，并担任运营副总裁。Yerace先生在制药行业拥有超过十年的经验，是负责供应链管理、业务发展、投资组合管理和企业战略的关键战略家。Yerace先生拥有广泛的运营经验，曾在小型私营公司和世界500强跨国公司的采购、全球供应链管理、运营和业务发展方面担任领导职务。在加入Coeptis之前，Yerace先生曾担任Kadmon Pharmaceuticals全球供应链和商业业务发展高级总监。Yerace先生拥有经济学学士学位，韦恩斯堡大学工商管理硕士学位。
- Daniel Yerace has over ten years of experience in the pharmaceutical industry and is a key strategist responsible for supply chain management, biness development, portfolio management, and corporate strategy. Mr. Yerace has broad operational experience and has held leadership positions in procurement, global supply chain management, operations, and biness development for small private firms and fortune 500 multi national corporations. Prior to joining Coeptis, Mr. Yerace served as Senior Director of Global Supply Chain and Commercial Biness Development for Kadmon Pharmaceuticals. Mr. Yerace holds a bachelor's degree in economics, and a masters of biness administration from Waynesburg University.
- Brian Cogley
Brian Cogley，2023年5月开始担任Coeptis Therapeutics Holdings，Inc. 首席财务官。他拥有超过15年的会计和财务经验，此前曾在两家“四大”会计师事务所担任越来越权威的职位，并曾在多个行业的多家公司的管理团队任职。Cogley先生是一名受过培训的会计师，他在Coeptis拥有15年的公司财务和会计职业生涯，在此期间，他为跨越多个行业的公司提供咨询和领导财务运营，包括生命科学、制药、金融服务和制造业。最近，Cogley先生担任CFGI，LLC会计咨询高级经理，在那里他为制药和金融服务客户提供技术会计实施和执行、临时财务总监角色、临时SEC报告经理角色、分部报告和剥离业务方面的服务。在加入CFGI之前，Cogley先生曾在NexTier Bank担任财务与会计副总裁一职，是该公司高级管理团队的成员，并领导该公司的会计和财务业务，包括总分类账、财务规划和分析、内部和外部财务报告以及人力资源。在加入NexTier之前，Cogley先生曾担任Calgon Carbon Corporation的全球现金经理一职，负责全球企业的所有日常现金决策。在加入卡尔冈炭素之前，Cogley先生是TriState Capital银行的金融分析师，负责构建其Sarbanes-Oxley控制环境、SEC/监管报告和新系统实施，同时还从事各种工艺改进项目。Cogley先生的职业生涯始于KPMG，LLP，为金融服务行业的各种客户提供审计和鉴证服务。科格利先生获得了杜肯大学会计学专业的学士学位和金融学专业的工商管理硕士学位。
Brian Cogley arrives at Coeptis with a career in corporate finance and accounting during which he advised and led the financial operations for companies spanning multiple indtries including life sciences, pharmaceuticals, financial services, and manufacturing. From February 2022 until joining Coeptis, Mr. Cogley was a Senior Manager, Accounting Advisory at CFGI, LLC where he served pharmaceutical and financial services clients in technical accounting implementations and execution, interim Controller roles, interim SEC Reporting Manager roles, segment reporting and carve out engagements. From 2017 2022 Mr. Cogley held the position of Vice President of Finance & Accounting at NexTier Bank where he was a member of the Company's senior management team and led its accounting and finance operations, including the general ledger, financial planning and analysis, internal and external financial reporting, and human resces. From 2015 2017 Mr. Cogley held the position of Global Cash Manager for Calgon Carbon Corporation, where he was responsible for all daily cash decisions across the global enterprise. From 2012 2015 Mr. Cogley was a Financial Analyst at TriState Capital Bank where he was responsible for building its Sarbanes Oxley control environment, SEC/regulatory reporting and new system implementation, while also working on vario process improvement projects. Mr. Cogley began his career at KPMG, LLP, providing audit and assurance services to a variety of clients in the financial services industry. Mr. Cogley earned a B.A. with a concentration in accounting and a Master of Biness Administration with a concentration in finance from Duquesne University.- Brian Cogley，2023年5月开始担任Coeptis Therapeutics Holdings，Inc. 首席财务官。他拥有超过15年的会计和财务经验，此前曾在两家“四大”会计师事务所担任越来越权威的职位，并曾在多个行业的多家公司的管理团队任职。Cogley先生是一名受过培训的会计师，他在Coeptis拥有15年的公司财务和会计职业生涯，在此期间，他为跨越多个行业的公司提供咨询和领导财务运营，包括生命科学、制药、金融服务和制造业。最近，Cogley先生担任CFGI，LLC会计咨询高级经理，在那里他为制药和金融服务客户提供技术会计实施和执行、临时财务总监角色、临时SEC报告经理角色、分部报告和剥离业务方面的服务。在加入CFGI之前，Cogley先生曾在NexTier Bank担任财务与会计副总裁一职，是该公司高级管理团队的成员，并领导该公司的会计和财务业务，包括总分类账、财务规划和分析、内部和外部财务报告以及人力资源。在加入NexTier之前，Cogley先生曾担任Calgon Carbon Corporation的全球现金经理一职，负责全球企业的所有日常现金决策。在加入卡尔冈炭素之前，Cogley先生是TriState Capital银行的金融分析师，负责构建其Sarbanes-Oxley控制环境、SEC/监管报告和新系统实施，同时还从事各种工艺改进项目。Cogley先生的职业生涯始于KPMG，LLP，为金融服务行业的各种客户提供审计和鉴证服务。科格利先生获得了杜肯大学会计学专业的学士学位和金融学专业的工商管理硕士学位。
- Brian Cogley arrives at Coeptis with a career in corporate finance and accounting during which he advised and led the financial operations for companies spanning multiple indtries including life sciences, pharmaceuticals, financial services, and manufacturing. From February 2022 until joining Coeptis, Mr. Cogley was a Senior Manager, Accounting Advisory at CFGI, LLC where he served pharmaceutical and financial services clients in technical accounting implementations and execution, interim Controller roles, interim SEC Reporting Manager roles, segment reporting and carve out engagements. From 2017 2022 Mr. Cogley held the position of Vice President of Finance & Accounting at NexTier Bank where he was a member of the Company's senior management team and led its accounting and finance operations, including the general ledger, financial planning and analysis, internal and external financial reporting, and human resces. From 2015 2017 Mr. Cogley held the position of Global Cash Manager for Calgon Carbon Corporation, where he was responsible for all daily cash decisions across the global enterprise. From 2012 2015 Mr. Cogley was a Financial Analyst at TriState Capital Bank where he was responsible for building its Sarbanes Oxley control environment, SEC/regulatory reporting and new system implementation, while also working on vario process improvement projects. Mr. Cogley began his career at KPMG, LLP, providing audit and assurance services to a variety of clients in the financial services industry. Mr. Cogley earned a B.A. with a concentration in accounting and a Master of Biness Administration with a concentration in finance from Duquesne University.
- Christine Sheehy
Christine Sheehy，从Coeptis Therapeutics Holdings，Inc.开始担任公司的首席财务官，直到2023年5月。Sheehy女士在制药行业拥有超过25年的经验，包括在全球范围内将药物产品商业化，并致力于开发包括细胞和基因疗法在内的靶向疗法。2017年至今，她担任Coeptis Therapeutics Holdings，Inc.董事、首席财务官和秘书。从2010年到2016年，Sheehy女士担任Kadmon Pharmaceuticals的运营高级副总裁，Kadmon Pharmaceuticals是一家临床和商业期制药公司。2001年至2010年，她担任三江制药运营副总裁，这是一家初创制药公司，于2010年被Kadmon Pharmaceuticals收购。在此期间，她在美国推出了品牌和仿制药产品，引领了运营业务。Sheehy女士获得了宾夕法尼亚州立大学会计学学士学位。
Christine Sheehy has over 25 years of experience in the pharmaceutical biness, including globally commercializing drug products and working in development of targeted therapeutics including cell and gene therapies. Since 2017, she has served as Director, Chief Financial Officer and Secretary. From 2010 to 2016, Ms. Sheehy served as the Senior Vice President of Operations for Kadmon Pharmaceuticals, a clinical and commercial phase pharmaceutical company. From 2001 to 2010, she served as the Vice President of Operations of Three Rivers Pharmaceuticals, a start up pharmaceutical company which was acquired by Kadmon Pharmaceuticals in 2010. During that time, she launched branded and generic products in the U.S., leading the operational biness. Ms. Sheehy earned a bachelor's degree in accounting from Penn State University.- Christine Sheehy，从Coeptis Therapeutics Holdings，Inc.开始担任公司的首席财务官，直到2023年5月。Sheehy女士在制药行业拥有超过25年的经验，包括在全球范围内将药物产品商业化，并致力于开发包括细胞和基因疗法在内的靶向疗法。2017年至今，她担任Coeptis Therapeutics Holdings，Inc.董事、首席财务官和秘书。从2010年到2016年，Sheehy女士担任Kadmon Pharmaceuticals的运营高级副总裁，Kadmon Pharmaceuticals是一家临床和商业期制药公司。2001年至2010年，她担任三江制药运营副总裁，这是一家初创制药公司，于2010年被Kadmon Pharmaceuticals收购。在此期间，她在美国推出了品牌和仿制药产品，引领了运营业务。Sheehy女士获得了宾夕法尼亚州立大学会计学学士学位。
- Christine Sheehy has over 25 years of experience in the pharmaceutical biness, including globally commercializing drug products and working in development of targeted therapeutics including cell and gene therapies. Since 2017, she has served as Director, Chief Financial Officer and Secretary. From 2010 to 2016, Ms. Sheehy served as the Senior Vice President of Operations for Kadmon Pharmaceuticals, a clinical and commercial phase pharmaceutical company. From 2001 to 2010, she served as the Vice President of Operations of Three Rivers Pharmaceuticals, a start up pharmaceutical company which was acquired by Kadmon Pharmaceuticals in 2010. During that time, she launched branded and generic products in the U.S., leading the operational biness. Ms. Sheehy earned a bachelor's degree in accounting from Penn State University.